Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Mar 23;403(10432):1164-1175.
doi: 10.1016/S0140-6736(23)02844-1. Epub 2024 Feb 22.

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial

Magnus Ochoge  1 , Ahmed Cherno Futa  1 , Ama Umesi  1 , Lucy Affleck  1 , Larry Kotei  1 , Baboucarr Daffeh  1 , Ebrima Saidy-Jah  1 , Anna Njie  1 , Oluwafemi Oyadiran  1 , Bassey Edem  1 , Musa Jallow  1 , Edrissa Jallow  1 , Simon A Donkor  1 , Erman Tritama  2 , Talha Abid  3 , Kathryn A V Jones  3 , Bernardo A Mainou  3 , John O Konz  4 , Alan Fix  4 , Chris Gast  4 , Ed Clarke  5
Affiliations
Clinical Trial

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial

Magnus Ochoge et al. Lancet. .

Abstract

Background: Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of circulating vaccine-derived polioviruses. This trial aimed to provide key safety and immunogenicity data required for nOPV2 licensure and WHO prequalification.

Methods: This phase 3 trial recruited infants aged 18 to <52 weeks and young children aged 1 to <5 years in The Gambia. Infants randomly assigned to receive one or two doses of one of three lots of nOPV2 or one lot of bivalent OPV (bOPV). Young children were randomised to receive two doses of nOPV2 lot 1 or bOPV. The primary immunogenicity objective was to assess lot-to-lot equivalence of the three nOPV2 lots based on one-dose type 2 poliovirus neutralising antibody seroconversion rates in infants. Equivalence was declared if the 95% CI for the three pairwise rate differences was within the -10% to 10% equivalence margin. Tolerability and safety were assessed based on the rates of solicited adverse events to 7 days, unsolicited adverse events to 28 days, and serious adverse events to 3 months post-dose. Stool poliovirus excretion was examined. The trial was registered as PACTR202010705577776 and is completed.

Findings: Between February and October, 2021, 2345 infants and 600 young children were vaccinated. 2272 (96·9%) were eligible for inclusion in the post-dose one per-protocol population. Seroconversion rates ranged from 48·9% to 49·2% across the three lots. The minimum lower bound of the 95% CIs for the pairwise differences in seroconversion rates between lots was -5·8%. The maximum upper bound was 5·4%. Equivalence was therefore shown. Of those seronegative at baseline, 143 (85·6%) of 167 (95% CI 79·4-90·6) infants and 54 (83·1%) of 65 (71·7-91·2) young children seroconverted over the two-dose nOPV2 schedule. The post-two-dose seroprotection rates, including participants who were both seronegative and seropositive at baseline, were 604 (92·9%) of 650 (95% CI 90·7-94·8) in infants and 276 (95·5%) of 289 (92·4-97·6) in young children. No safety concerns were identified. 7 days post-dose one, 78 (41·7%) of 187 (95% CI 34·6-49·1) infants were excreting the type 2 poliovirus.

Interpretation: nOPV2 was immunogenic and safe in infants and young children in The Gambia. The data support the licensure and WHO prequalification of nOPV2.

Funding: Bill & Melinda Gates Foundation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ET works for PT Biofarma who manufacture the novel oral poliovirus vaccine type 2 and the bivalent oral poliovirus vaccine used in this trial. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Trial profile (A) Infants trial profile. (B) Young children trial profile. All young children randomly assigned to nOPV2 received lot 1 of the vaccine. bOPV=bivalent oral poliovirus vaccine. nOPV2=novel oral poliovirus vaccine type 2.
Figure 2
Figure 2
Poliovirus type 2 serum neutralising antibody seroprotection rates, geometric mean titres, and seroconversion rates in infants and young children (A) Infant seroprotection rates and geometric mean poliovirus type 2 neutralising antibody concentrations. (B) Infant post-dose one and post-dose two overall seroconversion rates and seroconversion rates in baseline seronegative and baseline seropositive infants. (C) Young children seroprotection rates and geometric mean poliovirus type 2 neutralising antibody concentrations. (D) Young children post-dose one and post-dose two overall seroconversion rates and seroconversion rates in baseline seronegative and baseline seropositive young children. Solid bars indicate seroprotection or seroconversion rates (left axis). Lines represent geometric mean type 2 serum neutralising antibody titres (right axis). Geometric mean titres and 95% CIs are estimated via the maximum likelihood based on survival methods including censoring at the lower limit of quantification and upper limit of quantification when appropriate. Seroprotection is defined as the percentage of participants with a reciprocal serum neutralising antibody titre of 8 or higher. Seroconversion (baseline seronegative) is defined as the percentage of participants with a post-dose reciprocal serum neutralising antibody titre of 8 or higher among those participants with a baseline reciprocal serum neutralising antibody titre of less than 8. Seroconversion (baseline seropositive) is defined as the percentage of participants with a post-dose four-fold rise in reciprocal serum neutralising antibody titres among those with a baseline reciprocal serum neutralising antibody titre of 8 or higher. This includes only those participants in whom a four-fold rise in reciprocal neutralising antibody titres was evaluable based on the baseline titre and upper limit of quantification for the assay. Seroconversion overall combined the seronegative and seropositive participants undergoing seroconversion. Exact Clopper-Pearson CIs are provided for seroprotection and seroconversion rates.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Global Polio Eradication Initiative Polio today. https://polioeradication.org/polio-today/
    1. Global Polio Eradication Initiative Polio eradication strategy 2022–2026: delivering on a promise. 2022. https://polioeradication.org/gpei-strategy-2022-2026/
    1. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8 - PMC - PubMed
    1. WHO Global polio eradication initiative. Circulating vaccine-derived polioviruses, global update. August, 2020. https://polioeradication.org/wp-content/uploads/2020/12/20201118_cVDPV2_...
    1. Voorman A, Lyons H, Bennette C, et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2023;41(suppl 1):A85–A92. - PMC - PubMed

Publication types